Catheter Precision, Inc. IPO — what the S-1 filing reveals | StockTools

ipo radar // reading the prospectusLOADING

Catheter Precision, Inc.

Registered to go public · latest filing 424B3 on 2026-07-10

what the prospectus reveals // AI read of the S-1

Catheter Precision (NYSE American: VTAK) designs, manufactures and sells medical technologies focused on cardiac electrophysiology (heart rhythm) treatment, based on the historical business of the former Catheter Precision it merged with in January 2023. Through its 82%-owned subsidiary Cardionomix, it also acquired assets related to a Cardiac Pulmonary Nerve Stimulation (CPNS) System for late-stage treatment of acute conditions. Importantly, this filing is a resale prospectus registering shares held by existing investors and preferred-stock holders \u2014 the company states it will NOT receive any proceeds from sales under this prospectus.

Financials: The provided excerpt does not clearly state revenue, growth, or profit/loss figures; detailed financial statements are incorporated by reference rather than included in this text.

Use of proceeds: The company states it will not receive any proceeds from sales under this prospectus (the selling stockholders receive all proceeds), though it will incur registration expenses.

strengths it claims

The company operates in the cardiac electrophysiology field with what it describes as 'new and innovative medical technologies,' and has expanded its pipeline via the Cardionomix asset acquisition of a novel CPNS System.
Its Common Stock is already listed and trading on the NYSE American under the symbol 'VTAK,' providing an existing public market.
The company has been able to raise capital through multiple private placements (Series C, D, and J preferred stock financings) with accredited investors, indicating some access to funding.

risks it discloses

Massive potential dilution: the filing registers 68,067,042 resale shares, largely from conversions of Series C, D and J preferred stock, and explicitly warns this 'could cause substantial dilution to our existing stockholders.'
The conversion terms use a Floor Price of just $0.35 per share \u2014 far below the July 9, 2026 market price of $1.14 \u2014 meaning many more shares could be issued as the stock price falls, magnifying dilution.
The company receives none of the proceeds from these sales; the money goes to selling stockholders, while the company bears the registration costs.
Selling stockholders may resell large blocks of stock at prevailing or negotiated prices at any time, which could pressure the share price.
The business carries the risks typical of a small-cap medical device company reliant on repeated private financings, and its industry/market estimates are based partly on management's own assumptions that may prove inaccurate.

⚠ This is a resale registration that could flood the market with tens of millions of new shares \u2014 with a conversion floor price ($0.35) well below the recent trading price ($1.14) \u2014 posing a substantial risk of dilution and downward price pressure for existing holders.

The AI read is generated from the company’s own SEC S-1/424B prospectus and may miss nuance — read the filing before relying on it. A prospectus is written to sell the offering. An S-1 registration doesn’t guarantee an IPO will happen, or when. Educational only, not financial advice, and never a recommendation to buy or sell.